Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study

Zekai Huang1,*
Shaolei Li1,*
Xin Yang2
Fangliang Lu1
Miao Huang1
Shanyuan Zhang1
Ying Xiong1
Panpan Zhang1
Jiahui Si1
Yuanyuan Ma1
Yue Yang1

1Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China; 2Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China

*These authors contributed equally to this work

Purpose: The role of neoadjuvant chemotherapy and subsequent adjuvant therapy in the treatment of patients with locally advanced esophageal squamous cell carcinomas (ESCC) is not well established.

Patients and methods: We retrospectively reviewed 228 patients with locally advanced ESCC receiving esophagectomy following neoadjuvant chemotherapy from January 2007 through December 2016. The probabilities of disease-free survival (DFS) and overall survival (OS) were estimated by means of the Kaplan–Meier method and were compared with the use of the log-rank test. Univariate and multivariate analyses of predictors of DFS and OS were performed using a Cox proportional-hazards model. Propensity score matching analysis was performed for further analysis regarding the benefit of adjuvant therapy.

Results: The pathological complete response of neoadjuvant chemotherapy was achieved in 13 of 228 patients (5.7%). With a median follow-up of 59.6 months, the median DFS and OS were 35.4 and 45.4 months, respectively. The multivariate Cox model determined chemotherapy regimens and ypT category were significant independent predictors of both DFS and OS and ypN category was also a significant independent predictor of OS. However, these patients did not seem to benefit from subsequent adjuvant therapy. The necessity of adjuvant therapy requires further investigation.

Conclusion: Surgery following neoadjuvant chemotherapy was applicable. Chemotherapy regimens and ypT category were significant independent predictors of both DFS and OS and ypN category was also a significant independent predictor of OS. However, these patients did not seem to benefit from subsequent adjuvant therapy. The necessity of adjuvant therapy requires further investigation.

Keywords: locally advanced esophageal squamous cell carcinoma, neoadjuvant chemotherapy, surgery, adjuvant therapy

Introduction

Esophageal cancer is the sixth most common cause of cancer deaths in the world, leading to 509,000 deaths occurred in 2018 worldwide. Moreover, it is the third most commonly diagnosed cancers of men, fifth of women, and one of the five leading causes of cancer death of both men and women in China. Additionally, 90% of cases are squamous cell carcinomas in China, compared with about 26% in the USA (among white individuals).1,2
The role of neoadjuvant chemotherapy is equivocal because data supporting benefits are lacking and randomized trials comparing surgery alone with surgery following neoadjuvant chemotherapy in patients with locally advanced resectable esophageal cancer showed conflicting results. Although several randomized trials showed significant disease-free survival (DFS) and overall survival (OS) benefit favoring neoadjuvant chemotherapy over surgery alone, the long-term results of these studies highly varied. The efficacy of adjuvant therapy has been demonstrated in INT-0116 trial (postoperative chemoradiotherapy) and MAGIC trial (perioperative chemotherapy) in patients with resectable adenocarcinoma of the stomach or esophagogastric junction cancers. However, it is still unclear whether patients with esophageal squamous cell carcinoma (ESCC) will benefit from adjuvant therapy.

Therefore, we conducted this retrospective study to assess the influence of neoadjuvant chemotherapy and the subsequent adjuvant therapy, as well as the long-term survival of these patients.

Patients and methods

Patients

This study was approved by the Ethics Committee of the Peking University Cancer Hospital and Institute, Beijing, China. Written informed consent was obtained from all enrolled participants. All methods were applied according to the approved guidelines and regulations. We retrospectively reviewed all of the patients who underwent surgery following neoadjuvant chemotherapy for locally advanced resectable esophageal cancer at Department of Thoracic Surgery II, Peking University Cancer Hospital from January 2007 through December 2016. All patients underwent pretreatment staging, consisting of upper gastrointestinal endoscopy with histological biopsy and computed tomography (CT) scan of the neck, chest, and upper abdomen. Eligible patients were restaged according to the eighth American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) cancer staging system. Locally advanced resectable esophageal cancer was defined as clinical stage T1 N+, T2 or higher, any N. R0 resection was defined as complete resection with no tumor within 1 mm of the resection margins. R1 and R2 resections were defined as microscopically confirmed tumor cell residual and macroscopically confirmed tumor cell residual or M1, respectively. Only patients who underwent R0 resection with histologically confirmed, locally advanced resectable ESCC were eligible for inclusion in the analysis. The main exclusion criteria were adenocarcinoma or large-cell undifferentiated carcinoma of the esophagus or esophagogastric junction, R1 or R2 resection, and previous chemotherapy and/or radiotherapy.

Treatment

The chemotherapy regimens were usually based on paclitaxel plus cisplatin or paclitaxel plus nedaplatin (TP), accounting for 82.5%, and 188 patients received these regimens. Meanwhile, the following chemotherapy regimens were also used: paclitaxel plus carboplatin, irinotecan plus cisplatin, etoposide plus cisplatin, and docetaxel plus nedaplatin. Administration of neoadjuvant chemotherapy would be delayed or withheld in case of severe toxic effects. Surgery was regularly scheduled within 4–6 weeks after the completion of two cycles of neoadjuvant therapy. Operative approaches included Ivor–Lewis and McKeown esophagogastrectomy with regional lymphadenectomy. The postoperative adjuvant therapy including chemotherapy and/or radiotherapy was usually performed >1 month after resection. Postoperative adjuvant chemotherapy was performed for two to four cycles according to the efficacy of neoadjuvant chemotherapy. The postoperative radiotherapy dose was usually 41.4–50.4 Gy (1.8 or 2 Gy/fraction). Postoperative chemotherapy and radiotherapy were conducted sequentially if both were administered. After surgery, patient’s physical condition was assessed to see if he/she could tolerate postoperative treatment. Postoperative treatment was administered only in medically fit patients. For medically fit patients with downstaging, they were recommended to receive only postoperative chemotherapy with the same regimen as the preoperative one because chemotherapy is effective enough. For medically fit patients who had stable disease or progressive disease, postoperative chemoradiotherapy was recommended and these patients would receive another regimen of chemotherapy for the lack of response to the primary one. However, if these patients had acute toxicity toward preoperative chemotherapy, we recommended them to receive only postoperative radiotherapy for the sake of safety.

Follow-up

During the first 2 years after surgery, patients were reviewed every 3 months, and then every 6 months for 3–5 years. During follow-up, CT scan of thorax and ultrasonography of abdomen and neck were regularly carried out, and diagnostic investigation such as upper gastrointestinal endoscopy was carried out only when recurrence was suspected. Late toxic effects, disease recurrence, and death were documented meticulously. Additional examinations would be conducted,
if necessary, for patients with particular symptoms and signs. A combination of clinical service records, phone calls, and e-mails was used to determine every patient’s status by September 2017.

**Statistical analysis**

In this analysis, the DFS was defined as the interval between the date of surgery and the date of recurrence or date of last follow-up. And OS was defined as the interval between the date of surgery and the date of death or the date of the last follow-up. The probabilities of DFS and OS were estimated by means of the Kaplan–Meier method and were compared with the use of the log-rank test. A Cox proportional-hazards model was used for univariate and multivariate analyses. To avoid overdetermination, the multivariable model included only highly significant (P<0.20) univariate factors. To better compare survival between patients with and without receiving adjuvant therapy, propensity score matching was performed in order to reduce imbalance in patients and treatment characteristics. A balanced cohort was then created using a 1:1 nearest neighbor matching algorithm with a caliper of 0.02 of the SD of the propensity score on the logit scale. Results of analyses were considered significant at a level of P<0.05. Statistical analysis was performed using SPSS software (IBM SPSS version 24, Chicago, IL, USA).

**Results**

**Characteristics of the patients**

From January 2007 through December 2016, a total of 1,123 patients with esophageal cancer underwent surgery, of whom 256 patients received esophagectomy following preoperative chemotherapy. R0 resection was achieved in 243 of 256 patients (94.9%). According to the inclusion and exclusion criteria, 15 patients were excluded: 9 esophageal adenocarcinoma; 3 esophageal large-cell undifferentiated carcinoma; 3 receiving preoperative chemoradiation therapy. Finally, 228 patients were included into this analysis (Figure 1). Baseline clinicopathological characteristics of these patients are shown in Table 1.

**Follow-up and complications of surgery following neoadjuvant chemotherapy**

During follow-up, 94 patients who underwent resection following neoadjuvant chemotherapy died after having been discharged, of whom 92 (97.9%) patients died from recurrent cancer and 2 (2.1%) from infection. In 37 of 228 patients (16.2%), postoperative complications were observed; among them, 17 patients developed anastomotic fistula, 22 developed postoperative infection, and 9 developed hemorrhage.

**Survival**

For all patients, the median follow-up was 59.6 months. The median DFS was 35.4 months, and the estimated 3-, 5-, and 7-year DFS were 48.0%, 38.0%, and 36.0%, respectively. Separate curves for DFS according to clinical T category, clinical N category, ypT category, and ypN category are shown in Figure 2. The multivariate Cox proportional-hazards model determined that only chemotherapy regimens (others vs TP, HR =2.021, 95% CI =1.266–3.224, P=0.003) and ypT category (ypT3–4a vs ypT0–2, HR =2.035, 95% CI =1.230–3.368, P=0.006) were significant independent predictors of DFS (Table 2).

For the entire cohort, the median OS was 45.4 months and the estimated 3-, 5-, and 7-year OS were 55.0%, 46.0%, and 43.0%, respectively. Kaplan–Meier plots for OS according to clinical T category, clinical N category, ypT category, and ypN category are shown in Figure 3. Moreover, in the multivariate Cox proportional-hazards model, significant independent predictors of OS comprised chemotherapy regimens (others vs TP, HR =2.313, 95% CI =1.402–3.816, P=0.001), ypT category (ypT3–4a vs ypT0–2, HR =3.241, 95% CI =1.877–5.599, P<0.001), and ypN category (ypN1–3 vs ypN0, HR =3.653, 95% CI =1.312–10.174, P=0.013; Table 3).

**Adjuvant therapy**

There were no significant survival differences between groups with and without adjuvant therapy regarding OS.
chemotherapy regimens (P=0.005), ypT category (P=0.009), and ypN category (P=0.007) were significantly different between patients with and without receiving adjuvant therapy. The matched cohort consisted of 81 patients in each arm, and all covariates included in the propensity score were well balanced after matching. In propensity matched cohort, there was no significant benefit found in either DFS (P=0.251) or OS (P=0.374; Figure 4C,D).

Discussion

In this retrospective analysis, we reviewed 228 R0 resected patients with esophageal squamous cell cancer who underwent esophagectomy following neoadjuvant chemotherapy. Surgery following neoadjuvant chemotherapy was applicable, associated with a low frequency of postoperative complications rate (16.2%). Furthermore, chemotherapy regimens and ypT category were significant independent predictors of both DFS and OS. We also found out that these patients did not seem to benefit from adjuvant therapy.

With a median follow-up of 59.6 months, the median DFS was 35.4 months, and the median OS was 45.4 months. The 5-year DFS rate and OS rate were 38% and 46%, respectively. It is noteworthy that the long-term results of the CROSS trial reported a survival outcome with a median progression-free survival of 74.4 months and a median OS of 81.6 months for patients with squamous cell carcinomas in the neoadjuvant chemoradiotherapy plus surgery group, albeit the population was small (41 patients).10 This trial indicated that preoperative chemoradiotherapy may be more effective than preoperative chemotherapy. However, we need to note that currently there is no high-quality, multicenter, large-sample standard randomized trials directly comparing neoadjuvant chemoradiotherapy plus surgery group, albeit the population was small (41 patients).11 This trial indicated that preoperative chemoradiotherapy may be more effective than preoperative chemotherapy. However, we need to note that currently there is no high-quality, multicenter, large-sample standard randomized trials directly comparing neoadjuvant chemoradiotherapy plus surgery and neoadjuvant chemotherapy plus surgery for patients with locally advanced resectable ESCCs. Thus, the best preoperative treatment strategy remains controversial, and further clinical randomized trials are needed.

There is controversy in the treatment of esophageal cancer for patients who have clinical complete response (cCR) after chemoradiotherapy. A standard treatment is to offer these patients an esophagectomy. However, there is a study indicating that cCR after chemoradiotherapy may mean surgery is not always needed because the addition of surgery to thoracic locally advanced esophageal carcinoma patients with a cCR after preoperative chemoradiotherapy did not benefit long-term survival.11 Currently, this area remains controversial due to the lack of randomized controlled trials directly comparing surveillance to surgery in patients who have had a cCR to preoperative treatment.

### Table 1 Characteristics of patients

| Variables | Number (%) |
|-----------|------------|
| Age (years) | |<| |
| ≥60 | 117 (51.3) |
| <60 | 111 (48.7) |
| Sex | |<| |
| Male | 197 (86.4) |
| Female | 31 (13.6) |
| Smoking history | |<| |
| No | 77 (33.8) |
| Yes | 151 (66.2) |
| History of alcohol | |<| |
| No | 87 (38.2) |
| Yes | 141 (61.8) |
| Downstaging | |<| |
| No | 153 (67.1) |
| Yes | 75 (32.9) |
| Lesion location | |<| |
| U | 34 (14.9) |
| M | 80 (35.1) |
| L | 114 (50.0) |
| Chemotherapy regimen | |<| |
| TP | 188 (82.5) |
| Others | 40 (17.5) |
| Surgery procedure | |<| |
| Ivor–Leouis | 149 (65.4) |
| McKeown | 79 (34.6) |
| Tumor thrombus | |<| |
| Negative | 181 (79.4) |
| Positive | 47 (20.6) |
| Adjuvant therapy | |<| |
| No | 103 (45.2) |
| Yes | 125 (54.8) |
| Clinical T category | |<| |
| cT1–2 | 11 (4.8) |
| cT3–4a | 217 (95.2) |
| Clinical N category | |<| |
| cN0 | 59 (25.9) |
| cN1–3 | 169 (74.1) |
| ypT category | |<| |
| ypT0–2 | 91 (39.9) |
| ypT3–4a | 137 (60.1) |
| ypN category | |<| |
| ypN0 | 106 (46.5) |
| ypN1–3 | 122 (53.5) |

Abbreviations: U, upper; M, middle; L, lower; TP, paclitaxel plus cisplatin or paclitaxel plus nedaplatin.

(P=0.184). Furthermore, patients who did not receive any adjuvant therapy seemed to have a better DFS compared with those who did (P=0.001). The results are shown in the Figure 4A,B. In order to further examine these findings, a secondary analysis using propensity score matching was performed to reduce imbalance in patients and treatment characteristics. Characteristics of patients in full cohort and propensity score matched cohort are shown in Table 4. Before propensity score matching, tumor downstaging (P=0.021),
Figure 2 Curves of disease-free survival.

Notes: (A) By clinical T category. (B) By clinical N category. (C) By ypT category. (D) By ypN category.

Table 2 Univariable and multivariable analyses of disease-free survival

| Variables                  | Univariable analysis | Multivariable analysis |
|----------------------------|----------------------|------------------------|
|                            | HR (95% CI)         | P-value | aHR (95% CI) | P-value |
| Age (years)                |                      |          |              |         |
| ≥60                        | Reference            |          | Reference    |          |
| <60                        | 0.913 (0.628–1.326) | 0.632    | 1.009 (0.677–1.506) | 0.963 |
| Sex                        |                      |          |              |         |
| Male                       | Reference            |          | Reference    |          |
| Female                     | 0.906 (0.525–1.562) | 0.721    | 1.124 (0.539–2.344) | 0.755 |
| Smoking history            |                      |          |              |         |
| No                         | Reference            |          |              |         |
| Yes                        | 0.755 (0.515–1.106) | 0.149    | 0.795 (0.505–1.252) | 0.322 |
| History of alcohol         |                      |          |              |         |
| No                         | Reference            |          |              |         |
| Yes                        | 0.851 (0.583–1.243) | 0.404    |              |         |
| Downstaging                |                      |          |              |         |
| No                         | Reference            |          | Reference    |          |
| Yes                        | 0.53 (0.345–0.814)  | 0.004    | 1.204 (0.537–2.700) | 0.653 |
| Lesion location            |                      |          |              |         |
| U                          | Reference            | 0.186    | Reference    |          |
| M                          | 1.663 (0.888–3.112) | 0.112    | 1.487 (0.784–2.821) | 0.225 |
| L                          | 1.749 (0.956–3.201) | 0.07     | 1.594 (0.830–3.062) | 0.161 |
| Chemotherapy regimen       |                      |          |              |         |
| TP                         | Reference            |          | Reference    |          |
| Others                     | 2.198 (1.418–3.407) | <0.001   | 2.021 (1.266–3.224) | 0.003 |

(Continued)
Table 2 (Continued)

| Variables                        | Univariable analysis |          | Multivariable analysis |          |
|----------------------------------|----------------------|----------|------------------------|----------|
|                                  | HR (95% CI)          | P-value  | aHR (95% CI)           | P-value  |
| Surgery procedure                |                      |          |                        |          |
| Ivor–Lewis                       | Reference            |          |                        |          |
| McKeown                          | 0.794 (0.533–1.183)  | 0.256    |                        |          |
| Tumor thrombus                   |                      |          |                        |          |
| Negative                         | Reference            |          |                        |          |
| Positive                         | 1.835 (1.184–2.842)  | 0.007    |                        |          |
| Adjuvant therapy                 |                      |          |                        |          |
| No                               | Reference            |          |                        |          |
| Yes                              | 1.892 (1.274–2.811)  | 0.002    |                        |          |
| Clinical T category              |                      |          |                        |          |
| cT1–2                            | Reference            |          |                        |          |
| cT3–4a                           | 1.154 (0.506–2.630)  | 0.733    |                        |          |
| Clinical N category              |                      |          |                        |          |
| cN0                              | Reference            |          |                        |          |
| cN1–3                            | 1.592 (1.006–2.521)  | 0.047    |                        |          |
| ypT category                     |                      |          |                        |          |
| ypT0–2                           | Reference            |          |                        |          |
| ypT3–4a                          | 2.359 (1.549–3.593)  | <0.001   | 2.035 (1.230–3.368)    | 0.006    |
| ypN category                     |                      |          |                        |          |
| ypN0                             | Reference            |          |                        |          |
| ypN1–3                           | 2.028 (1.377–2.988)  | <0.001   | 1.838 (0.736–4.593)    | 0.193    |

**Abbreviation:** aHR, adjusted hazard ratio.

Figure 3 Curves of overall survival.

Notes: (A) By clinical T category. (B) By clinical N category. (C) By ypT category. (D) By ypN category.
With regard to chemotherapy regimens, the multivariate Cox proportional-hazards model demonstrated that patients administered with paclitaxel plus cisplatin or paclitaxel plus nedaplatin (TP) had a significantly better survival (both DFS and OS). Although the safety and efficacy of a single agent including paclitaxel, nedaplatin, carboplatin, irinotecan, etoposide, and docetaxel are confirmed, adequately powered Phase III studies are lacking to determine the best combination of chemotherapy regimens. The value of this specific finding will need to be assessed in future randomized controlled studies.

ypT category was demonstrated to be the significant independent predictor of both DFS and OS. However, ypN category was not a significant independent predictor of survival. Obviously, the 7–8th AJCC/UICC cancer staging system emphasizing on the number of nodes rather than their anatomic

| Variables                  | Univariable analysis | Multivariable analysis |
|----------------------------|----------------------|------------------------|
|                           | HR (95% CI)          | P-value                | aHR (95% CI)   | P-value |
| **Age (years)**            |                      |                        |                |         |
| ≥60                       | Reference            |                        |                |         |
| <60                       | 0.998 (0.665–1.498)  | 0.992                  | Reference      | 1.211 (0.779–1.882) | 0.394 |
| **Sex**                   |                      |                        |                |         |
| Male                      | Reference            |                        |                |         |
| Female                    | 0.946 (0.526–1.703)  | 0.853                  | Reference      | 1.681 (0.806–3.504) | 0.166 |
| **Smoking history**       |                      |                        |                |         |
| No                        | Reference            |                        |                |         |
| Yes                       | 0.864 (0.568–1.316)  | 0.496                  | Reference      |                |         |
| **History of alcohol**    |                      |                        |                |         |
| No                        | Reference            |                        |                |         |
| Yes                       | 0.911 (0.603–1.376)  | 0.657                  | Reference      |                |         |
| **Downstaging**           |                      |                        |                |         |
| No                        | Reference            |                        |                |         |
| Yes                       | 0.533 (0.334–0.849)  | 0.008                  | Reference      | 2.128 (0.875–5.171) | 0.096 |
| **Lesion location**       |                      |                        |                |         |
| U                         | Reference            |                        |                |         |
| M                         | 2.172 (1.045–4.515)  | 0.038                  | Reference      | 2.314 (1.090–4.912) | 0.029 |
| L                         | 2.247 (1.101–4.586)  | 0.026                  | Reference      | 2.243 (1.039–4.843) | 0.040 |
| **Chemotherapy regimen**  |                      |                        |                |         |
| TP                        | Reference            |                        |                |         |
| Others                    | 2.077 (1.304–3.310)  | 0.002                  | Reference      | 2.313 (1.402–3.816) | 0.001 |
| **Surgery procedure**     |                      |                        |                |         |
| Ivor–Lewis                | Reference            |                        |                |         |
| McKeown                   | 0.76 (0.494–1.171)  | 0.214                  | Reference      |                |         |
| **Tumor thrombus**        |                      |                        |                |         |
| Negative                  | Reference            |                        |                |         |
| Positive                  | 1.77 (1.092–2.869)  | 0.020                  | Reference      | 0.988 (0.571–1.707) | 0.964 |
| **Adjuvant therapy**      |                      |                        |                |         |
| No                        | Reference            |                        |                |         |
| Yes                       | 1.321 (0.871–2.003)  | 0.190                  | Reference      | 0.935 (0.609–1.437) | 0.760 |
| **Clinical T category**   |                      |                        |                |         |
| cT1–2                     | Reference            |                        |                |         |
| cT3–4a                    | 0.977 (0.426–2.238)  | 0.956                  | Reference      |                |         |
| **Clinical N category**   |                      |                        |                |         |
| cN0                       | Reference            |                        |                |         |
| cN1–3                     | 2.166 (1.247–3.763)  | 0.003                  | Reference      | 0.967 (0.397–2.357) | 0.941 |
| **ypT category**          |                      |                        |                |         |
| ypT0–2                    | Reference            |                        |                |         |
| ypT3–4a                   | 2.738 (1.707–4.392)  | <0.001                 | Reference      | 3.241 (1.877–5.599) | <0.001 |
| **ypN category**          |                      |                        |                |         |
| ypN0                      | Reference            |                        |                |         |
| ypN1–3                    | 2.503 (1.623–3.859)  | <0.001                 | Reference      | 3.653 (1.312–10.174) | 0.013 |

Abbreviation: aHR, adjusted hazard ratio.
locations is controversial compared with 11th Japan Esophageal Society (JES) staging,\textsuperscript{21,22} even though there is a study indicating that N staging for 7–8th AJCC/UICC cancer staging system and 11th JES staging system showed similar predictive power for DFS.\textsuperscript{23} Besides, prognostication based on cT differed from that based on ypT reflects inaccuracies of obtaining cancer facts by current clinical staging modalities, including ineffectual use of clinical staging modalities, inaccurate evaluation of clinical cancers, and unpredictability of effectiveness of neoadjuvant treatment (downstaging) of advanced cancers. Therefore, a more accurate cancer staging system is needed.

The role of adjuvant therapy for patients with ESCC who have received preoperative therapy is not yet established.\textsuperscript{24} In this study, we found that patients did not seem to benefit from adjuvant therapy. Moreover, the multivariate Cox proportional-hazards model demonstrated that patients who received adjuvant therapy had a worse DFS than those did not (yes vs no, HR, 1.498 [0.996–2.252], \(P=0.052\)). After using propensity score matching method to reduce imbalance in patients and treatment characteristics, still there was no significant benefit found in DFS (\(P=0.251\)) or OS (\(P=0.374\)). This finding needs further investigations and the reason for that remains unknown. However, our finding is comparable to some randomized trials of postoperative therapy\textsuperscript{25–27} and a meta-analysis,\textsuperscript{28} which came to a conclusion that postoperative chemotherapy did not add a survival benefit to surgery. Meanwhile, the National Comprehensive Cancer Network (NCCN) guidelines suggest that for patients with ESCC who have received preoperative therapy, no further treatment is necessary (irrespective of their nodal status) if there is no residual disease at surgical margins (R0 resection). This area remains an active subject of investigation.

A possible limitation of our study is that these patients with esophageal cancer receiving esophagectomy following preoperative chemotherapy did not receive totally consistent chemotherapy regimens. Besides, existence of confounding factors is inevitable due to the inherent nature of retrospective analysis. Therefore, results from this study might not be readily extrapolated. Nevertheless, this retrospective study provides an opportunity to assess the safety and long-term survival benefit for patients who underwent neoadjuvant chemotherapy followed by surgery. We believe this analysis will make a positive contribution given the lack of definitive evidence from randomized clinical trials.

---

**Figure 4** Curves of survival with and without adjuvant therapy.  
**Notes:** (A) Curves of disease-free survival in full cohort. (B) Curves of overall survival in full cohort. (C) Curves of disease-free survival in propensity matched cohort. (D) Curves of overall survival in propensity matched cohort.
**Conclusion**

Our results showed that neoadjuvant chemotherapy followed by esophagectomy was an applicable treatment strategy for locally advanced ESCC. Chemotherapy regimens and ypT category were significant independent predictors of both DFS and OS. The adjuvant therapy following neoadjuvant chemotherapy and R0 resection did not seem to show survival benefit and its necessity requires further investigations.

**Acknowledgments**

We thank Servbus Technology (Beijing) Co., Ltd for the database support and statistical analysis. This work was supported by National Key R&D Program of China No. 2018YFC0910700, Peking University Medicine Seed Fund for Interdisciplinary Research (BMU2018MX008), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special funding (No. ZYLX201509) and

---

**Table 4** Characteristics of patients in full cohort and propensity score matched cohort

| Variables                          | Full cohort | P-value | Matched cohort | P-value |
|-----------------------------------|-------------|---------|----------------|---------|
|                                   | Adjuvant therapy |         | Adjuvant therapy |         |
|                                   | No (n=103) | Yes (n=125) |                  | No (n=81) | Yes (n=81) |
| Age (years)                       |             |         |                 |         |
| ≥60                               | 55 (63.4)  | 62 (49.6)  | 0.568           | 40 (49.4)  | 41 (50.6)  | 0.875 |
| <60                               | 48 (46.6)  | 63 (50.4)  |                 | 41 (50.6)  | 40 (49.4)  |
| Sex                               |             |         |                 |         |
| Male                              | 86 (83.5)  | 111 (88.8) | 0.245           | 69 (85.2)  | 69 (85.2)  | 1.000 |
| Female                            | 17 (16.5)  | 14 (11.2)  |                 | 12 (14.8)  | 12 (14.8)  |
| Smoking history                   |             |         |                 |         |
| No                                | 36 (35.0)  | 41 (32.8)  | 0.732           | 25 (30.9)  | 29 (35.8)  | 0.505 |
| Yes                               | 67 (65.0)  | 84 (67.2)  |                 | 56 (69.1)  | 52 (64.2)  |
| History of alcohol                |             |         |                 |         |
| No                                | 43 (41.7)  | 44 (35.2)  | 0.311           | 28 (34.6)  | 32 (39.5)  | 0.515 |
| Yes                               | 60 (58.3)  | 81 (64.8)  |                 | 53 (65.4)  | 49 (60.5)  |
| Downstaging                       |             |         |                 |         |
| No                                | 61 (59.2)  | 92 (73.6)  | 0.021           | 54 (66.7)  | 55 (67.9)  | 0.867 |
| Yes                               | 42 (40.8)  | 33 (26.4)  |                 | 27 (33.3)  | 26 (32.1)  |
| Lesion location                   |             |         |                 |         |
| U                                 | 18 (17.5)  | 16 (12.8)  | 0.586           | 14 (17.3)  | 11 (13.6)  | 0.498 |
| M                                 | 34 (33.0)  | 46 (36.8)  |                 | 26 (32.1)  | 33 (40.7)  |
| L                                 | 51 (49.5)  | 63 (50.4)  |                 | 41 (50.6)  | 37 (45.7)  |
| Chemotherapy regimen              |             |         |                 |         |
| TP                                | 93 (90.3)  | 95 (76.0)  | 0.005           | 72 (88.9)  | 71 (87.7)  | 0.807 |
| Others                            | 10 (9.7)   | 30 (24.0)  |                 | 9 (11.1)   | 10 (12.3)  |
| Surgery procedure                 |             |         |                 |         |
| Ivor–Lewis                        | 65 (63.1)  | 84 (67.2)  | 0.518           | 48 (59.3)  | 54 (66.7)  | 0.329 |
| McKeown                           | 38 (36.9)  | 41 (32.8)  |                 | 33 (40.7)  | 27 (33.3)  |
| Tumor thrombus                    |             |         |                 |         |
| Negative                          | 85 (82.5)  | 96 (76.8)  | 0.288           | 65 (80.2)  | 65 (80.2)  | 1.000 |
| Positive                          | 18 (17.5)  | 29 (23.2)  |                 | 16 (19.8)  | 16 (19.8)  |
| Clinical T category               |             |         |                 |         |
| cT1–2                             | 5 (4.9)    | 6 (4.8)    | 0.985           | 5 (6.2)    | 4 (4.9)    | 0.732 |
| cT3–4a                            | 98 (95.1)  | 119 (95.2) |                 | 76 (93.8)  | 77 (95.1)  |
| Clinical N category               |             |         |                 |         |
| cN0                               | 32 (31.1)  | 27 (21.6)  | 0.104           | 20 (24.7)  | 21 (25.9)  | 0.857 |
| cN1–3                             | 71 (68.9)  | 98 (78.4)  |                 | 61 (75.3)  | 60 (74.1)  |
| ypT category                      |             |         |                 |         |
| ypT0–2                            | 25 (24.3)  | 14 (11.2)  | 0.009           | 32 (39.5)  | 34 (42.0)  | 0.749 |
| ypT3–4a                           | 78 (75.7)  | 111 (88.8) |                 | 49 (60.5)  | 47 (58.0)  |
| ypN category                      |             |         |                 |         |
| ypN0                              | 58 (56.3)  | 48 (38.4)  | 0.007           | 39 (48.1)  | 38 (46.9)  | 0.875 |
| ypN1–3                            | 45 (43.7)  | 77 (61.6)  |                 | 42 (51.9)  | 43 (53.1)  |
National Natural Science Foundation of China (Grant number: 81772494 and 81502578).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. Kelsen DP, Ginsberg R, Rajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339(27):1979–1984.
4. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719–3725.
5. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–5067.
6. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–1733.
7. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastrooesophageal junction. N Engl J Med. 2001;345(10):725–730.
8. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastric adenocarcinoma. N Engl J Med. 2006;355(1):11–20.
9. Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol. 2017;12(1):36–42.
10. Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for esophageal or junctional cancer (cross): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098.
11. Wang J, Qin J, Jing S, et al. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: is esophagectomy always necessary? A systematic review and meta-analysis. Thorac Cancer. 2018;9(12):1638–1647.
12. Leichman L, Berry BT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol. 1991;18(1 Suppl 3):64–72.
13. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-H infusion in advanced esophageal cancer. Ann Oncol. 2007;18(5):898–902.
14. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86(14):1086–1091.
15. Muir-Wilkenshoff F, Hinkelbein W, Ohnesorge I, et al. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis. 2003;18(4):330–334.
16. Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005;50(12):2218–2223.
17. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–959.
18. El-Rayes BF, Shields A, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol. 2004;15(6):960–965.
19. Harstrick A, Bokemeyer C, Preusser P, et al. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol. 1992;29(4):321–322.
20. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–1724.
21. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus. 2017;14(1):1–36.
22. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part II and III. Esophagus. 2017;14(1):37–65.
23. Park SY, Kim DJ, Suh JW, Byun GE. Comparison of the 11th Japanese classification and the AJCC 7th and 8th staging systems in esophageal squamous cell carcinoma patients. J Thorac Dis. 2018;10(8):5039–5046.
24. Cohen DJ, Leichman L. Controversies in the treatment of local and locally advanced gastric and esophageal cancers. J Clin Oncol. 2015;33(16):1754–1759.
25. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet. 1989;1(8638):571–574.
26. Macdonald JS, Fleming TR, Peterson RF, et al. Adjuvant chemotherapy with 5-FU, Adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a southwest Oncology Group study. Ann Surg Oncol. 1995;2(6):488–494.
27. Allum WH, Hallissey MT, Ward LC, Hockey MS. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer. 1989;60(5):739–744.
28. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441–1447.